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 51 
Abstract 52 
Background: Abnormal liver enzymes are frequently encountered in inflammatory bowel disease 53 
(IBD) patients. Infliximab has been implicated in inducing drug-induced liver injury, autoimmune 54 
hepatitis or reactivation of HBV. We aimed to clarify the role of infliximab to liver impairment in an 55 
IBD cohort. 56 
Study: 305 patients with IBD, without evidence of chronic liver disease, were included in the study 57 
and retrospectively evaluated. Laboratory and clinical data were retrieved from a prospectively 58 
acquired database. 176 consecutive patients treated with infliximab during the last 5 years were 59 
compared to a matched population of 129 patients that did not receive any anti-TNF treatment. 60 
Results: Elevation of ALT was frequent in the whole population (36.4%) and it was not significantly 61 
associated with the use of infliximab (P=0.284). Elevations more than 3ULN were observed in 7.9% 62 
and these spontaneously resolved in 83%. The use of immunomodulators was the only factor that was 63 
significantly associated with liver enzyme abnormalities in multivariate analysis (OR 2.666, 95% CI 64 
1.576-4.511, p<0.005). 39% of patients on infliximab had elevated liver enzymes and this was 65 
associated with increased ALT before starting infliximab (OR 3.854, 95% CI 1.800-8.251, P=0.001) 66 
and with longer duration of infliximab treatment (OR 1.030, 95% CI 1.013-1.047, P=0.001).  67 
Conclusion: Elevated liver enzymes are frequently found in IBD patients and they usually 68 
spontaneously resolve. The use of immunomodulators was independently associated with increased 69 
ALT. Infliximab is relatively safe in terms of liver impairment and discontinuation of treatment is 70 
rarely required in the setting of modest elevations of ALT.   71 
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 77 
Introduction 78 
Inflammatory bowel diseases (IBD), consisting mainly of Crohn’s disease (CD) and ulcerative colitis 79 
(UC) are complex immune-mediated multifactorial gastrointestinal disorders [1]. Intestinal 80 
inflammation is a result of aberrant activation of T-cell response to commensal enteric flora in 81 
genetically susceptible hosts [2].   This chronic inflammatory process is characterized by periods of 82 
relapse and remission. 83 
 IBD therapy aims to induce and sustain remission as long as possible. Multiple therapeutic agents 84 
have been used for this purpose. Aminosalicylates, corticosteroids, thiopurines, methotrexate, 85 
cyclosporine and more recently tumor necrosis factor (TNFa) antibodies have been proven efficient 86 
in inducing and maintaining clinical remission in patients with active CD or UC [3].  87 
 However, most of these agents have been linked to some extent to hepatotoxicity. Almost all 88 
immunosuppressive regimens used in IBD have been reported to increase hepatic enzymes, 89 
sometimes necessitating drug discontinuation [4].  90 
Infliximab is a chimeric monoclonal antibody that binds avidly to tumor necrosis factor α, resulting 91 
in its inactivation. It is currently indicated for CD, UC and several rheumatologic disorders[5]. 92 
Infliximab was considered to be a safe medication in terms of liver impairment even though it is 93 
known to result in asymptomatic elevation of liver enzymes[6-8]. Post-marketing reports however 94 
have shown that severe liver injury can be induced by this agent resulting even in liver transplantation 95 
[9]. 96 
The aim of this study was to define the true incidence of liver impairment related to infliximab in a 97 
real life IBD cohort and to compare it to an IBD control group not receiving this medication. As a 98 
secondary endpoint we tried to correlate the ALT levels with clinical events that could lead to 99 
potential discontinuation or change of treatment.  100 
 101 
 102 
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Materials and Methods 103 
 104 
Study population  105 
All consecutive IBD patients treated with infliximab from 2008-2013 in the Department of 106 
Gastroenterology, Royal Free Hospital, London, were retrospectively evaluated. The diagnoses of 107 
CD and UC were established by standard clinical, radiological, histological, and endoscopic criteria 108 
[10, 11]. Patients diagnosed with known liver related disease, such as primary sclerosing cholangitis 109 
(PSC) or chronic viral hepatitis, were excluded from the study. Laboratory parameters were obtained 110 
the day before infliximab induction as baseline and all subsequent follow up blood tests (full blood 111 
count and liver enzymes) were recorded. Elevation of transaminases was categorized as mild, 112 
moderate or severe (ALT ≤2ULN, ALT= 2-3ULN, ALT≥3ULN respectively). In those patients with 113 
raised liver enzymes post infliximab, we retrospectively checked their liver biochemistry up to one 114 
year before baseline and we recorded any other events of liver impairment during that time. Data 115 
were retrieved from medical records regarding concomitant medications, especially those potentially 116 
related to hepatotoxicity (immunomodulators, aminosalicylates, antibiotics). Liver enzymes were 117 
recorded until each patient’s last follow-up.  118 
The same parameters were obtained from a control group of IBD patients, who did not receive any 119 
anti-TNF agent and were matched by gender, type of IBD and duration of follow-up to the study 120 
group.  121 
 122 
Definitions 123 
Abnormality or increase of liver enzymes was defined as any elevation in alanine transaminase (ALT 124 
upper limit of normal (ULN) 33 U/l), aspartate transaminase (AST ULN 31 U/l), alkaline phosphatase 125 
(ALP ULN 129 U/l), γ-glutamyl transferase (gGT ULN 36 U/l) and/or bilirubin (Bil ULN 21 μmol/l). 126 
Elevation of transaminases was defined as mild in ALT ≤ 2ULN, moderate in ALT x2-3ULN and 127 
significant in ALT≥3ULN. The R value was calculated as the ratio [ALT/ALT ULN : ALP/ALP 128 
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ULN]. R≥5 corresponds to a hepatocellular pattern of drug-induced liver injury (DILI), R≤2 to a 129 
cholestatic pattern and R between 2 and 5 is defined as a mixed type of DILI[12]. 130 
 131 
Treatment 132 
All patients treated with Infliximab were taking the standard regimen dose of 5mg/kg at weeks 0, 2, 133 
6 and every 8 weeks thereafter [13]. Total duration of treatment in months was recorded. The use of 134 
azathioprine, 6-mercaptopurine, methotrexate, aminosalicylates and steroids was recorded when they 135 
were prescribed during the period of the study. Full blood count and liver biochemistry were 136 
monitored every 8 weeks for patients on infliximab and every 3-6 months for the rest of the 137 
population.  138 
 139 
Statistical analysis 140 
Data were expressed as mean and standard deviation (SD) for continuous and normally distributed 141 
variables, median and range for continuous variables without normal distribution, or frequencies 142 
(percentage) for categorical variables. For comparisons the chi-square test was used for categorical 143 
variables; the Student’s t - test and the Mann-Whitney test for continuous variables with or without 144 
normal distribution, respectively. For comparisons between more than two groups, the Kruskal-145 
Wallis test was applied. Univariate analysis was used to identify parameters associated with abnormal 146 
ALT. Multiple logistic regression was used for multivariate analysis. The level of statistical 147 
significance was set at p≤0.05. Statistical analysis was performed using the Statistical Package for 148 
Social Sciences, version 22 (SPSS, IL, Chicago). 149 
 150 
 151 
 152 
 153 
 154 
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Results 155 
 156 
Patients’ characteristics 157 
One hundred and seventy six IBD patients were treated with infliximab between 2008 and 2013 and 158 
met the inclusion criteria for the study. As a control group, one hundred and twenty nine IBD patients 159 
(129) out of the total IBD population treated in the Gastroenterology Department were selected.  In 160 
total, 305 patients with IBD were included in the study. Thirteen patients were evaluated and excluded 161 
due to other liver related diseases: 5 with concomitant PSC, 3 with HCV, 1 with established cirrhosis 162 
and 4 with active CMV viremia. 163 
Mean age was 40 ± 14.7 years and 164 were males (53.8%). 223/305 (73%) had Crohn’s disease and 164 
82 had ulcerative colitis. Mean duration of infliximab treatment was 23.1±21.7 months. 165 
Cumulative percentages for use of each drug during the 5 year follow up were: infliximab 57.7%, 166 
azathioprine 40.7%, 6-mercaptopurine 13.1%, aminosalicylates 21% and steroids 7.2%. These are 167 
summarized in Table 1. 168 
 169 
Abnormal liver enzymes in the infliximab population 170 
176/305 patients (57.7%) were treated with infliximab and ALT increase was observed in 69 (39.2%) 171 
of them, with spontaneous resolution in 76% of cases. Mean age was 37.8±14.1 years, 105/176 172 
(59.7%) were males and 138/176 (80%) had Crohn’s disease. All patients had been checked for 173 
hepatotropic viruses prior to initiation of infliximab (HAV, HBV, HCV, CMV, EBV, VZV). 174 
Nearly half of them were taking immunomodulators, i.e azathioprine, 6-MP or methotrexate. Of the 175 
69 patients who received infliximab, mean duration of treatment was 23.1±21.7 months, 31 (44.9%) 176 
had an elevation of ALT within the first 3 months of treatment and 41 (59%) had at least one episode 177 
of elevated liver enzymes one year prior [Table 2]. 37 (53.6%) patients had autoimmune testing 178 
on appearance of abnormal liver tests and 12 (32%) had positive antinuclear antibodies but 179 
with low titres (less than 1:80) and normal immunoglobulins. 180 
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These 69 patients were compared to the rest of the infliximab subpopulation that did not have any 181 
ALT abnormality during the period of the study (n=107).  No statistically significant difference was 182 
found among age (P=0.654), gender (P=0.152), diagnosis (UC or CD) (P=0.219) and use of 183 
immunomodulators, aminosalicylates or steroids between the two groups (P=0.235, P=0.713 and 184 
P=0.699 respectively). 25/69 (36.2%) of patients with ALT abnormalities after infliximab induction  185 
had also at least one episode of elevated ALT up to one year before, compared to 16/107 (15%) of 186 
those with normal liver enzymes post infliximab treatment (P=0.002). Mean duration of anti-TNF 187 
treatment was 29.5 months in patients with abnormal liver enzymes, and this was significantly longer 188 
compared to patients with normal liver biochemistry; mean duration of infliximab treatment 11.5 189 
months, P<0.0005 [Table 3].  190 
In multivariate analysis, abnormal ALT in the subgroup of patients treated with infliximab was 191 
significantly associated with elevated ALT prior to infliximab induction (OR 3.854, 95% CI 1.800-192 
8.251, P=0.001) and longer duration of infliximab treatment (OR 1.030, 95% CI 1.013-1.047, 193 
P=0.001).  194 
 195 
Abnormal liver enzymes in the whole cohort 196 
111/305 patients (36.4%) were found to have at least one episode of elevated liver enzymes, which 197 
resolved spontaneously in 73% of cases. Time to resolution was less than three months in 43%of 198 
these patients. Thirty eight patients with prolonged time to resolution (48 %) had only mildly 199 
abnormal transaminases (<2 ULN), possibly reflecting a non-acute aetiology such as fatty liver 200 
disease. The elevation was moderate in 10.2% and severe in 7.9% of cases. Transaminases were 201 
predominantly elevated compared to cholestatic enzymes in the majority of patients (89.2%). Twelve 202 
patients (10.8%) had a preponderance of elevated cholestatic enzymes (ALP, GGT).  203 
We compared patients with normal ALT (194/305) to those with at least one ALT abnormality since 204 
entry into study (111/305). There was no significant difference in age (P=0.134), gender (P=0.165), 205 
IBD diagnosis (UC or CD) (P=0.262), anti-TNF treatment (P=0.284) and use of aminosalicylates or 206 
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steroids between the two groups (P=0.487 and P=0.240 respectively). 85/111 (76.6%) patients with 207 
abnormal ALT were taking immunomodulators compared to 105/194 (43.9%) with normal ALT and 208 
this was statistically significant (P=0.001). The correlation of immunomodulators to ALT 209 
abnormalities was also confirmed in multivariate analysis (OR 2.666, 95% CI 1.576-4.511, p<0.001), 210 
while use of infliximab, steroids or aminosalicylates, age, gender and diagnosis were not statistically 211 
significant (P=NS) [Table 4]. 212 
 213 
Patients with significant liver injury  214 
Twenty-four patients out of the whole cohort (24/305, 7.9%) had an ALT more than three times the 215 
upper limit of normal and twelve (50%) of them were treated with infliximab. All but one (95%) 216 
had Crohn’s disease. All were screened for HAV, HBV, HCV and CMV serology and found 217 
negative. The rest of liver screening tests, such as immunoglobulin G, ferritin, alpha1- antitrypsin, 218 
copper and ceruloplasmin levels were tested and found normal.  219 
4/24 patients (16.6%) had positive antinuclear antibodies (3/4 on anti-TNF). Thirteen patients 220 
(54.1%) of those with significant liver injury were under some immunomodulatory agent. Ultrasound 221 
and/or computed tomography of the liver was performed in the majority of patients, showing fatty 222 
liver in 10 (41.6%), other lesions such as gallstones or hemangiomata in 4 (16.6%) and normal 223 
findings in 6 (25%) [Table 5].  224 
All but one patient under infliximab had a hepatocellular type of damage with an R value>5. A 225 
cholestatic pattern of liver injury was found in four patients not on anti-TNF treatment. MCRP was 226 
performed in those with elevated cholestatic enzymes and there was no bile duct dilation or evidence 227 
of PSC.  228 
A liver biopsy was done in four patients (16.6%), three of whom were treated with infliximab. Liver 229 
histopathology revealed a probable drug-induced liver injury (DILI) in 3/4 patients and non-alcoholic 230 
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steatohepatitis in the other one. Of the three patients with established DILI one was on azathioprine, 231 
one on infliximab (which was discontinued) and one on combination of infliximab and 6-MP (6-MP 232 
was subsequently discontinued).   233 
ALT values normalised in 20/24 patients (83.3%). Out of the four patients with no spontaneous 234 
resolution of their abnormal ALT, one was on the infliximab group. Fatty infiltration of the 235 
liver was the cause of abnormal ALT (as confirmed by CT imaging) in two patients with 236 
persistent liver enzyme elevations and these were offered lifestyle changes and close monitoring. 237 
No obvious reason for an intermittently elevated ALT despite extensive investigation was found 238 
in the other two patients.  239 
Resolution occurred in 21/24 (87.5%) patients without discontinuation of IBD treatment. Infliximab 240 
was stopped in two patients: one with a biopsy showing DILI and one due to absence of response 241 
who was switched to adalimumab. Azathioprine was discontinued in one patient with a biopsy-proven 242 
DILI. 243 
 244 
Discussion 245 
Hepatobiliary manifestations in patients with IBD are relatively frequent [14]. In our study, we 246 
confirmed the increased prevalence of elevated liver enzymes in an IBD population and we found 247 
that this is not associated with infliximab treatment. Furthermore, we showed that these elevations 248 
are usually not severe and they spontaneously resolve in the majority of cases, thus rarely requiring 249 
specific management.  250 
Liver disease in IBD can develop due to an immune-mediated pathogenetic mechanism, as a 251 
complication of structural and pathophysiological changes due to IBD or from drug induced 252 
hepatotoxicity [15].  253 
Several liver conditions have been frequently associated with IBD, the most common being PSC. 254 
Nearly 80% of patients diagnosed with PSC have IBD and a percentage of up to 7% of IBD patients 255 
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will finally develop PSC [5]. Autoimmune hepatitis (AIH) more often occurs in UC patients than in 256 
general population [16]. Cholelithiasis is more common in CD patients than in matched controls and 257 
this is associated with bile salt absorption affected by the number of surgeries and extent of ileal 258 
resections [17]. Patients with IBD are also prone to thrombosis [18]. Portal or hepatic vein thrombosis 259 
can lead to portal hypertension and liver cirrhosis. Non-alcoholic fatty liver disease (NAFLD) appears 260 
to be more common in IBD patients,  with prevalence as high as 35% [17].  261 
Medications used for IBD treatment are greatly associated with hepatotoxicity. Thiopurines can result 262 
not only in asymptomatic liver enzyme elevation but also in DILI or even liver injury due to 263 
generation of reactive oxygen species, via oxidation of azathioprine or 6-mercaptopurine (6-MP) by 264 
xanthine oxidase [19]. Thiopurine methyltransferase (TPMT) is the enzyme that catalyzes 6-MP 265 
methylation and shows great variation in its activity due to multiple genetic polymorphisms. As a 266 
result, toxic metabolites such as 6-MMP can accumulate in some patients leading to a greater extent 267 
to liver impairment[20]. Moreover, azathioprine has been linked to nodular regenerative hyperplasia 268 
(NRH) of the liver and non-cirrhotic portal hypertension [12]. The prevalence of 6-MP and 269 
azathioprine-induced liver impairment varies in several studies. In a recent study of 3931 IBD 270 
patients, 95% of who were on azathioprine, the incidence of hepatotoxicity was 4% [13]. Earlier 271 
studies have reported higher incidence of abnormal liver enzymes in IBD patients treated with 272 
thiopurines (10-20%) [21, 22].    273 
5-ASA is probably the responsible hepatotoxic moiety of aminosalicylates. Abnormal hepatic 274 
biochemistry attributed to these agents has been described since 1989 [14]. The hepatotoxic potential 275 
of methotrexate was firstly recorded in patients treated for psoriasis several decades ago. However, 276 
few trials have been conducted in IBD patients so far. In a meta-analysis of 13 trials, Khan et al 277 
showed that liver injury induced by methotrexate occurs in a comparable incidence to that of 278 
thiopurines [15]. 279 
Infliximab (IFX) was initially approved for the treatment of moderate to severe Crohn’s disease and 280 
rheumatoid arthritis in 1998 [23]. Most serious side effects include an increase in frequency of 281 
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infections, allergic reactions and generation of autoantibodies (mostly antinuclear and double-282 
stranded DNA). Elevation of liver enzymes is relatively common due to infliximab but significant 283 
liver damage was considered to be extremely rare [24].  284 
Several case reports have been published reporting hepatitis, frequently immune-mediated, that 285 
occurred after infliximab induction and resolved after discontinuation of the drug [25-28]. In a recent 286 
study Ghabril et al. described 34 cases of DILI induced by anti-TNFs [9]. Most of them follow a 287 
hepatocellular pattern of injury, have an autoimmune background and resolve after discontinuation 288 
of treatment. Switching infliximab to adalimumab seems to be well tolerated, suggesting absence of 289 
cross-toxicity between the two agents [29]. 290 
 Reactivation of occult hepatitis B can result in liver impairment and it was firstly described in two 291 
rheumatologic patients that were treated with infliximab in 2003 [30, 31].  292 
In the ATTRACT study group, patients receiving infliximab for rheumatoid arthritis developed ANA 293 
and anti-ds DNA antibodies in 23% and 16% respectively versus 6% and 0% of placebo recipients 294 
[32]. Autoimmune hepatitis may accompany the positivity of autoantibodies with markedly elevated 295 
transaminases and a typical liver biopsy showing interface hepatitis with lymphoplasmacytic infiltrate 296 
[33].   297 
Infliximab may induce elevation of liver enzymes due to idiosyncratic drug reaction.  Jaundice is a 298 
rare finding and in most cases liver impairment resolves spontaneously. 299 
Overall, infliximab may result in liver abnormalities via different mechanisms, raising issues 300 
regarding its safety.  An Austrian consensus about infliximab use in IBD after ten years on the market 301 
proposes discontinuation of treatment in cases of significant liver enzymes’ elevations (more than 302 
3ULN) [7].   303 
In our study the prevalence of abnormal liver enzymes was remarkably high, nearly 40%. However, 304 
similarly high incidence of elevated liver tests has been reported before [34, 35]. In the majority of 305 
our population the elevation was mild to moderate and only few patients developed ALT≥3ULN. 306 
Even significant elevations tended to resolve without need for treatment discontinuation. 307 
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Immunomodulatory agents were the only significant predictors of abnormal ALT, a correlation 308 
previously reported [21, 22].  Of note, this association was not statistically significant in the 309 
infliximab population.    310 
The incidence of increased transaminases in our study was similar in both infliximab and non-311 
infliximab treated populations. Infliximab could possibly be associated with some cases of ALT 312 
abnormalities but these were mostly mild. Even with significantly increased aminotransferases, the 313 
outcome was favorable and treatment was discontinued in only one patient. The presence of 314 
abnormal ALT prior to infliximab induction was significantly related to abnormal ALT in post 315 
infliximab measurements, emphasizing that several conditions unrelated to anti-TNF therapy may 316 
impair the hepatobiliary parameters in IBD. Moreover, presence of significant ALT elevations 317 
prior to infliximab initiation should trigger a liver screen in order to identify pre-existing liver  318 
disease. 319 
Another interesting finding was that the duration of infliximab therapy was significantly associated 320 
with elevated liver enzymes. This group of patients requiring anti-TNF therapy for longer is usually 321 
unresponsive to conventional treatment with longer periods of relapse and hospitalizations. 322 
Continuously active IBD may be responsible for a proportion of these liver abnormalities.  323 
Ascertainment bias is another possible explanation of this finding as these patients are monitored 324 
more frequently than ones having a disease of indolent course.  325 
The main limitation of this study is that, due to its retrospective design, imaging procedures and liver 326 
biopsy were not performed in the whole cohort. Of note, 41% of patients having significant elevation 327 
of hepatic enzymes turned out to have a fatty liver in ultrasound or CT scans. Liver biopsy was also 328 
performed in a minority of patients (4/111 patients, 3.6%).  329 
In conclusion, elevation of liver enzymes in IBD is not uncommon but is usually mild and transient, 330 
resolving spontaneously in the majority of cases. Even significant abnormalities resolved 331 
spontaneously in more than two thirds of cases. These abnormalities are likely to be multifactorial. 332 
Treatment with infliximab was not associated with deranged ALT in our study, suggesting that this 333 
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agent is generally safe. ALT elevation should not necessarily dictate discontinuation of 334 
treatment, however investigations should be performed in order to identify the exact diagnosis 335 
and underlying liver disease should be excluded in patients treated with infliximab. Other 336 
possible etiologies should be considered in cases of persistent or significant ALT abnormalities and 337 
priority should be given to stopping immunomodulators first rather than infliximab. A liver biopsy 338 
can establish the diagnosis in patients with persistent unexplained transaminase elevation and guide 339 
further therapeutic decisions, particularly regarding the continuation of immunomodulators and/or 340 
infliximab. 341 
We therefore recommend a wait-and-watch strategy rather than immediate action in IBD patients 342 
with elevated liver enzymes.   A liver biopsy would be of most importance in these cases that do not 343 
spontaneously resolve in order to obtain the correct diagnosis. Infliximab could be maintained except 344 
for those cases of established and biopsy-proven DILIs, when thiopurines are excluded as the main 345 
cause of liver function test abnormalities or of significant unexplained ALT elevations. 346 
The optimal time point to decide upon further management in significant ALT elevations has not yet 347 
been clarified. In our study, resolution occurred usually within the first three months but this is not 348 
universal. Further prospective studies and histopathologic evaluation of similar populations could 349 
enlighten our knowledge about this common phenomenon. Moreover, the presence of other liver-350 
related etiologies, such as NAFLD, should always influence the final decision. 351 
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